Eight Roads-backed b-ONE Ortho ("b-ONE") announced that it has raised multi miliion RMB in its Series B financing, which is the largest RMB financing in the domestic orthopedic field in recent years. Our China Ventures team also participated in this round. 

Founded in 2015, b-ONE speciliazies in developing innovative orthopedic healthcare solutions to restore motion and improve surgical outcomes. The USFDA approved its propriety product, MOBIO, in October 2018, while in August last year, its JUVENO solution got approval. Currently, except for MicroPort Orthopedics, b-ONE is the only joint company in China that has been approved by both FDA and NMPA for its hip and knee implants. b-ONE's products have obtained approvals in Singapore, New Zealand, Vietnam, Thailand and other Southeast Asian regions. 

b-ONE will use the funds to develop new materials and the next generation of digital orthopedic products, enrich and improve the product line, expand the domestic and international markets to promote product sales. In addition, b-ONE will also carry out plant reconstruction and expansion, adding automated assembly lines and expanding production capacity to cope with the increasing sales of future products.